Insider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells 5,000 Shares of Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 5,000 shares of Janux Therapeutics stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total value of $300,000.00. Following the completion of the transaction, the chief executive officer now directly owns 293,054 shares of the company’s stock, valued at $17,583,240. This represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

David Alan Campbell also recently made the following trade(s):

• On Tuesday, December 24th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $56.19, for a total transaction of $1,404,750.00.
• On Tuesday, December 3rd, David Alan Campbell sold 15,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $67.00, for a total transaction of $1,005,000.00.
• On Monday, November 25th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $51.60, for a total transaction of $1,290,000.00.
• On Monday, October 28th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $53.54, for a total value of $1,338,500.00.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX traded down $6.99 during midday trading on Wednesday, reaching $50.82. 2,261,422 shares of the stock were exchanged, compared to its average volume of 1,402,304. Janux Therapeutics, Inc. has a 12 month low of $7.79 and a 12 month high of $71.71. The company has a market capitalization of $2.67 billion, a price-to-earnings ratio of -43.44 and a beta of 3.23. The business has a 50-day simple moving average of $54.48 and a two-hundred day simple moving average of $48.16.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The business had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The company’s revenue was down 82.6% compared to the same quarter last year. Equities research analysts expect that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Stifel Nicolaus upped their price target on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. HC Wainwright raised their target price on shares of Janux Therapeutics from $63.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Lifesci Capital upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. UBS Group started coverage on shares of Janux Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price objective on the stock. Finally, Scotiabank lifted their target price on shares of Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 4th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $89.90.

Institutional Trading of Janux Therapeutics

A number of large investors have recently bought and sold shares of the business. Plato Investment Management Ltd boosted its holdings in shares of Janux Therapeutics by 18.7% in the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock valued at $54,000 after buying an additional 187 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after purchasing an additional 339 shares in the last quarter. Amalgamated Bank raised its stake in shares of Janux Therapeutics by 61.1% in the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after purchasing an additional 368 shares during the period. Virtu Financial LLC lifted its holdings in shares of Janux Therapeutics by 48.0% in the third quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after purchasing an additional 2,419 shares in the last quarter. Finally, Zacks Investment Management boosted its position in shares of Janux Therapeutics by 8.7% during the third quarter. Zacks Investment Management now owns 42,133 shares of the company’s stock worth $1,914,000 after buying an additional 3,360 shares during the period. 75.39% of the stock is owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.